Loading...
01/10 16:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
Consolidated Revenue EUR 66.3 million, a 3.5% decrease year-over-year. Reasons include macroeconomic headwinds and unfavorable foreign exchange effects, mainly due to a weaker U.S. dollar.
Gross Profit Margin 56.8%, slightly below the 57.2% achieved in Q3 2024. Reasons include stable gross profit but lower revenue.
Adjusted EBIT EUR 2.9 million, down from EUR 4.4 million in Q3 2024, representing a 4.4% margin. Reasons include lower revenue and cost control measures.
Net Profit EUR 1.8 million, compared to a net financial loss of EUR 1.1 million in Q3 2024. Reasons include improved financial results and limited foreign exchange losses.
Materialise Medical Revenue EUR 33.3 million, a 10% increase year-over-year. Reasons include growth in both medical software and medical device sales.
Materialise Software Revenue EUR 10.3 million, a 7% decrease year-over-year. Reasons include unfavorable foreign exchange impacts and macroeconomic/geopolitical uncertainty.
Materialise Manufacturing Revenue EUR 22.7 million, a 17% decrease year-over-year. Reasons include macroeconomic headwinds and weak performance in the automotive sector.
Adjusted EBITDA (Consolidated) EUR 8.4 million, down from EUR 9.9 million in Q3 2024, representing a 12.7% margin. Reasons include lower revenue but stable quarter-over-quarter performance due to cost control.
Materialise Medical Adjusted EBITDA EUR 10.2 million, with a margin of over 30%. Reasons include strong revenue growth and increased R&D investments.
Materialise Software Adjusted EBITDA EUR 1.8 million, with a margin of 18%. Reasons include effective cost management despite lower revenue.
Materialise Manufacturing Adjusted EBITDA Negative EUR 0.8 million, stable quarter-over-quarter. Reasons include lower revenue due to macroeconomic headwinds.
Operating Cash Flow EUR 10.4 million, up from EUR 6.9 million in Q3 2024. Reasons include strong free cash flow generation.
Capital Expenditures (CapEx) EUR 5.3 million, including EUR 3.1 million of non-recurring CapEx. Reasons include investments in machinery for the new ACTech plant and a solar panel park.
Cardiac Segment Expansion: Progress in the cardiac segment with the acquisition of FEops, specializing in AI-driven simulation technology for structural heart interventions. Released the next version of FEops' heart guide for transcatheter aortic valve replacement, adding predictive simulation features for reintervention planning. Clinical evidence demonstrated time savings of up to 91% for transcatheter aortic valve replacement procedures.
Mimics Enlight CMF Planner: Released a new version with AI algorithms for faster and more efficient planning, targeting trauma cases. Enables surgeons to plan procedures efficiently, saving costs and time during surgeries.
CO-AM Ecosystem: Launched low-code enabling technology to make SDKs more accessible, facilitating workflow automation and driving efficiencies in additive manufacturing operations.
Defense Sector Engagement: Increased focus on the defense sector, showcasing additive manufacturing capabilities at major trade exhibitions. Additive manufacturing addresses challenges in the defense industry, such as rapid and sustainable production of mission-critical components.
ACTech Expansion: Investments in machines for giga castings and large, complex parts for sectors like aquaculture, mining, maritime, and energy. Opened a second ACTech plant in 2024, enabling automation for small series production.
Revenue Growth in Medical Segment: Materialise Medical achieved an all-time revenue record of EUR 33.3 million in Q3 2025, growing by over 10% compared to Q3 2024. Growth driven by both medical software and medical device sales.
Cost Management: Disciplined cost control and targeted cost reduction measures stabilized adjusted EBIT and EBITDA compared to Q2 2025.
Transition to Cloud Subscription Model: Continued transition in the Software segment to a cloud subscription-based business model, with 83% of software revenue being recurring in Q3 2025, up from 74% in Q3 2024.
Focus on R&D Investments: Increased R&D investments, particularly in the Medical segment, to drive future growth.
Revenue Pressure: Overall revenue remained under pressure, with a 3.5% decline compared to the same quarter last year, driven by macroeconomic headwinds and unfavorable foreign exchange effects.
Manufacturing Segment Weakness: The Manufacturing segment experienced a 17% revenue decline year-over-year, attributed to macroeconomic challenges and weak demand in key sectors like automotive.
Software Segment Decline: The Software segment saw a 7% revenue decline, impacted by unfavorable foreign exchange rates and geopolitical uncertainty, particularly in the U.S. market.
Macroeconomic Headwinds: Macroeconomic volatility and geopolitical uncertainty continue to impact sales volumes and operational results across multiple segments.
Foreign Exchange Impact: Unfavorable foreign exchange effects, particularly due to a weaker U.S. dollar, negatively impacted revenue.
Cost Pressures: While cost control measures have been implemented, the company faces ongoing pressure to manage operational costs amidst declining revenues in key segments.
Deferred Revenue Decline: Deferred revenue related to software maintenance and license fees decreased in the third quarter, reflecting seasonal patterns but also indicating potential challenges in sustaining recurring revenue.
Defense Sector Challenges: While the company is making progress in the defense sector, the geopolitical landscape and breakdown of traditional alliances present uncertainties in this market.
Revenue Guidance for FY 2025: Materialise maintains its revenue guidance for fiscal year 2025 in the range of EUR 265 million to EUR 280 million.
Adjusted EBIT Guidance for FY 2025: The company expects adjusted EBIT to be in the range of EUR 6 million to EUR 10 million for fiscal year 2025.
Market Conditions Impact: Macroeconomic and geopolitical uncertainties continue to impact the business environment, particularly in the Manufacturing and Software segments.
Medical Segment Growth: Materialise Medical segment continues to grow, with plans to further increase R&D investments to drive future growth.
Software Segment Transition: The company is transitioning to a cloud subscription-based business model, with 83% of software revenue now recurring.
Manufacturing Segment Strategy: Materialise is investing in the huge and heavy segment, including machines for giga castings and large complex parts, to address challenges in sectors like automotive, aquaculture, mining, maritime, and energy.
Defense Sector Engagement: Materialise is expanding its presence in the defense sector, leveraging additive manufacturing to address industry challenges and strengthen strategic autonomy.
The selected topic was not discussed during the call.
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
The earnings call reveals a mixed performance with a 4% revenue increase but a significant drop in EBIT and net profit, indicating financial struggles. The guidance remains flat, and management's vague responses in the Q&A add uncertainty. Competitive pressures, regulatory issues, and economic factors pose risks. Despite positive cash flow and R&D investments, the negative trends in manufacturing and software revenues, coupled with unclear future projections, suggest a negative sentiment. The lack of market cap data prevents a more precise prediction, but the overall sentiment leans negative.
The earnings call highlights strong financial performance with a 14% revenue increase, improved margins, and successful acquisitions. Despite some management ambiguity during the Q&A, the optimistic guidance, new partnerships, and ongoing investments suggest positive market sentiment. The medical segment's growth and strategic partnerships are key catalysts for a potential stock price increase, likely in the 2% to 8% range.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
